Rabeprazole-d<sub>4</sub> (sodium salt)

Rabeprazole-d4 (sodium salt)

CAT N°: 26118
Price:

From 385.00 327.25

Rabeprazole-d4 is intended for use as an internal standard for the quantification of rabeprazole (Item No. 14939) by GC- or LC-MS. Rabeprazole is a proton pump inhibitor that selectively and irreversibly inhibits the gastric H+/K+ ATPase (IC50 = 72 nM).{23855} It can be activated more rapidly and over a greater pH range than other proton pump inhibitors such as omeprazole (Item No. 14880), lansoprazole (Item No. 13627), and pantoprazole (Item No. 21345).{23854} Rabeprazole (30 mg/kg) inhibits gastric acid secretion in pylorus-ligated rats and a rat model of gastric fistula.{47042} It also inhibits the growth of several strains of H. pylori in vitro (MIC50s = 1.57-3.13 ?g/mL).{23854} Formulations containing rabeprazole have been used in the treatment of ulcers, pathological hypersecretory conditions, and gastroesophageal reflux disease (GERD).

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole-4,5,6,7-d4, monosodium salt
  • Correlated keywords
    • E3810 Helicobacter E-3810 LY307640 LY-307640
  • Product Overview:
    Rabeprazole-d4 is intended for use as an internal standard for the quantification of rabeprazole (Item No. 14939) by GC- or LC-MS. Rabeprazole is a proton pump inhibitor that selectively and irreversibly inhibits the gastric H+/K+ ATPase (IC50 = 72 nM).{23855} It can be activated more rapidly and over a greater pH range than other proton pump inhibitors such as omeprazole (Item No. 14880), lansoprazole (Item No. 13627), and pantoprazole (Item No. 21345).{23854} Rabeprazole (30 mg/kg) inhibits gastric acid secretion in pylorus-ligated rats and a rat model of gastric fistula.{47042} It also inhibits the growth of several strains of H. pylori in vitro (MIC50s = 1.57-3.13 ?g/mL).{23854} Formulations containing rabeprazole have been used in the treatment of ulcers, pathological hypersecretory conditions, and gastroesophageal reflux disease (GERD).

We also advise you